chronic obstructive pulmonary disease, Sanofi and Dupixent
Sanofi blockbuster drug wins clearance in US for lung disease
Sanofi’s Dupixent has been cleared for a chronic lung disorder in the US, in another milestone for the blockbuster drug after a similar decision by European regulators.
FDA Approves Regeneron/Sanofi's Blockbuster Dupixent For Smoker's Lung Disease
On Friday, the FDA approved Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi SA’s (NASDAQ:SNY) Dupixent (dupilumab) as an add-on maintenance treatment of inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype,
Regeneron, Sanofi's Dupixent Get FDA Approval For Chronic Obstructive Pulmonary Disease Treatment
Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY), Friday announced that the U.S. Food and Drug Administration has approved
Chronic Obstructive Pulmonary Disease is Responsible for 3 Million Deaths a Year in the World
This pathology has a significant impact on patients' lives, including physical, emotional and economic consequences
Sanofi-Regeneron's Dupixent wins FDA's nod for 'smoker's lung'
The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a chronic lung disease, commonly known as "smoker's lung", the companies said on Friday.
Regeneron-Sanofi Drug Wins FDA Approval To Treat COPD
Key Takeaways Regeneron and Sanofi shares edged higher Friday after their drug to treat chronic obstructive pulmonary disease (COPD) received approval from the Food and Drug Administration (FDA).The drug,
US FDA approves Sanofi-Regeneron's Dupixent for 'smoker's lung'
Sanofi recorded 10.72 billion euros ($11.94 billion) in sales for Dupixent in 2023, which includes Regeneron's share. Analysts on average expect Dupixent, by far Sanofi's best-selling drug, to generate more than 21 billion euros in sales in 2030,
Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)
Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing ...
Exclusive: Understanding Chronic Lung Diseases And Co-Morbidities
MP Cariappa, Public Health Specialist, Advisor, Tata Trusts shares inputs on understanding chronic lung diseases. He is also ...
Rising Kashmir8d
Understanding COPD: A Chronic Lung Disease
Chronic obstructive lung disease, also known as chronic obstructive pulmonary disease (COPD), is a general term for a group ...
Commit To Care: The Power of Adherence In Chronic Respiratory Disease Treatment
With asthma and chronic obstructive pulmonary disease (COPD) on the rise, worsened by air pollution, tobacco use, and ...
Sixth Tone7d
China Adds Lung Disease to National Public Health Scheme
The move will enable the country’s more than 100 million chronic pulmonary disease patients to access free annual check-ups.
Too Old to Operate11d
Enhancing Pulmonary Rehabilitation in COPD with Virtual Reality
The following is a summary of “Virtual reality for COPD exacerbation: A randomized controlled trial,” published in the August ...
Medindia2d
Role of Mucin Sialylation in Muco-Obstructive Disorders
Discover how sugar modifications, particularly sialic acid, impact mucus formation and transport, contributing to diseases ...
Medscape3d
Loneliness/Disease Link Debatable?
Rather than a causal risk factor for diseases such as stroke, dementia, CVD, and psychiatric illness, loneliness may be a ...
The American Journal of Managed Care23h
COPD Poses Public Health Risk for US Smokers, Nonsmokers
While smoking is a key risk factor for chronic obstructive pulmonary disease (COPD), significant prevalence also exists among ...